Keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic NSCLC in adults whose tumours express PD-L1 with a ≥ 1% TPS...Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving Keytruda.

Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA

Pembrolizumab with pemetrexed and platinum chemotherapy is recommended as an option for untreated, metastatic, non squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)‑positive or anaplastic lymphoma kinase (ALK)‑positive mutations.

...Participant has histologically- or cytologically-confirmed metastatic non-squamous NSCLC with documented absence of a sensitizing EGFR, ALK, ROS-1, or BRAF V600E mutation or other genomic aberration for which an approved targeted therapy is available.. ...

...Participants must meet all of the following inclusion criteria to be eligible for participation in this study (no waivers for participant eligibility will be permitted).1)Participants assigned male at birth and participants assigned female at birth, 18 years of age or older, able to understand and give written informed consent.2)Life expectancy ≥ 3 months.3)Pathologically documented NSCLC that meets both of the criteria below:a)Have documented evidence of Stage IV NSCLC disease at the time of enrollment (based on AJCC, Eighth Edition).b)Have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations. ...

...patients that have actionable molecular targets (e.g., epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], c-ros oncogene 1[ROS1] mutations) must have received (when indicated) prior appropriate targeted therapy using Food and Drug Administration (FDA)-approved agents...

...In order to be eligible to participate in this study, a subject must meet all of the following criteria:• Histologically confirmed NSCLC, negative for EGFR and ALK mutations• WHO PS 0-2• No prior systemic therapy• High PD-L-1 expression (≥50% TPS)• High tumor burden (≥2 extrapulmonary metastases (M1c)) and not amenable for local consolidative therapies...

...Without activating mutation in EGFR or ALK chromosomal translocation....